menu
    • menu
    [{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Derazantinib","moa":"panFGFR kinase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Basilea Pharmaceutica \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Basilea Pharmaceutica \/ Not Applicable"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Derazantinib","moa":"panFGFR kinase","graph1":"Oncology","graph2":"Phase II","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Basilea Pharmaceutica \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Basilea Pharmaceutica \/ Not Applicable"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Derazantinib","moa":"FGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Basilea Pharmaceutica \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Basilea Pharmaceutica \/ Not Applicable"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Derazantinib","moa":"panFGFR kinase","graph1":"Oncology","graph2":"Phase II","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Basilea Pharmaceutica \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Basilea Pharmaceutica \/ Not Applicable"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Derazantinib","moa":"panFGFR kinase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Basilea Pharmaceutica \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Basilea Pharmaceutica \/ Not Applicable"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Derazantinib","moa":"panFGFR kinase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Basilea Pharmaceutica \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Basilea Pharmaceutica \/ Not Applicable"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Basilea Pharmaceutica","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"Ramucirumab","moa":"VEGFR2","graph1":"Oncology","graph2":"Approved","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Basilea Pharmaceutica \/ Basilea Pharmaceutica","highestDevelopmentStatusID":"12","companyTruncated":"Basilea Pharmaceutica \/ Basilea Pharmaceutica"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Derazantinib","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Basilea Pharmaceutica \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Basilea Pharmaceutica \/ Not Applicable"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Derazantinib","moa":"panFGFR kinase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Basilea Pharmaceutica \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Basilea Pharmaceutica \/ Not Applicable"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Derazantinib","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Basilea Pharmaceutica \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Basilea Pharmaceutica \/ Not Applicable"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Derazantinib","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Basilea Pharmaceutica \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Basilea Pharmaceutica \/ Not Applicable"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Derazantinib","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Basilea Pharmaceutica \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Basilea Pharmaceutica \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Derazantinib

    Menu

    Derazantinib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Basilea Pharmaceutica

                            Switzerland arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Basilea Pharmaceutica

                            Switzerland arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Derazantinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Basilea Reports Updated Interim Results for iCCA patients with FGFR2 Mutations and Amplifications from phase 2...

                            Details : BAL087 (derazantinib), an orally administered small-molecule FGFR inhibitor has demonstrated clinically meaningful efficacy with 74% disease control rate and median progression-free survival was 7.3 months in FIDES-01 study in patients iCCA.

                            Brand Name : BAL087

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 24, 2022

                            Lead Product(s) : Derazantinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Basilea Pharmaceutica

                            Switzerland arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Basilea Pharmaceutica

                            Switzerland arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Derazantinib,Paclitaxel,Ramucirumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Basilea Presents Preclinical Data on Synergy Between Derazantinib and Paclitaxel in Gastric Tumor Models At AN...

                            Details : The synergistic effect between derazantinib and paclitaxel is particularly encouraging as we are exploring derazantinib alone and in combination settings, including paclitaxel, in our clinical phase 1/2 study FIDES-03 in patients with gastric cancer.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 11, 2021

                            Lead Product(s) : Derazantinib,Paclitaxel,Ramucirumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Basilea Pharmaceutica

                            Switzerland arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Basilea Pharmaceutica

                            Switzerland arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Derazantinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Basilea Presents Full Safety and Efficacy Data Set on Derazantinib in Patients with Fgfr2 Fusion-Positive iCCA...

                            Details : Derazantinib is investigational orally administered small-molecule FGFR inhibitor with strong activity against FGFR1, 2, and 3. FIDES-01 study evaluated derazantinib, in patients with FGFR2 fusion-positive advanced or metastatic intrahepatic cholangiocar...

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 17, 2021

                            Lead Product(s) : Derazantinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Basilea Pharmaceutica

                            Switzerland arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Basilea Pharmaceutica

                            Switzerland arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Derazantinib,Atezolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Basilea Reports Derazantinib/PD-L1 Checkpoint Inhibitor Combination Results from Dose-Finding part of FIDES-02...

                            Details : The derazantinib-atezolizumab combination was well tolerated and no dose-limiting toxicities were observed. Finding from the cohort in the FIDES-02 study were presented at the virtual American Society of Clinical Oncology Genitourinary Cancers Symposium ...

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            February 12, 2021

                            Lead Product(s) : Derazantinib,Atezolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Basilea Pharmaceutica

                            Switzerland arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Basilea Pharmaceutica

                            Switzerland arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Derazantinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Basilea Reports +Ve Topline Results from P2 Study FIDES-01 for Derazantinib in FGFR2 Gene Fusion +ve Patients ...

                            Details : Clinical proof of concept achieved for derazantinib monotherapy in FGFR2 gene fusion-positive iCCA. Derazantinib has shown a well manageable safety profile.

                            Brand Name : BAL087

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            February 10, 2021

                            Lead Product(s) : Derazantinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Basilea Pharmaceutica

                            Switzerland arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Basilea Pharmaceutica

                            Switzerland arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ramucirumab,Derazantinib,Paclitaxel

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Basilea Pharmaceutica

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Basilea Announces Clinical Trial Collaboration and Supply Agreement with Eli Lilly and Company for Ramucirumab...

                            Details : The FIDES-03 study will assess the efficacy and safety of derazantinib as monotherapy and combination therapy with ramucirumab and paclitaxel or with Roche’s PD-L1 checkpoint inhibitor atezolizumab.

                            Brand Name : Cyramza

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            October 28, 2020

                            Lead Product(s) : Ramucirumab,Derazantinib,Paclitaxel

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Basilea Pharmaceutica

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Basilea Pharmaceutica

                            Switzerland arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Basilea Pharmaceutica

                            Switzerland arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Derazantinib,Ramucirumab,Paclitaxel

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Basilea Presents Preclinical Data on Anti-Angiogenic Activity of Derazantinib at ENA 2020

                            Details : The presented data from several preclinical models demonstrate that derazantinib has an anti-angiogenic effect, which may contribute to its overall anti-tumor activity in FGFR-driven cancers.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 26, 2020

                            Lead Product(s) : Derazantinib,Ramucirumab,Paclitaxel

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Basilea Pharmaceutica

                            Switzerland arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Basilea Pharmaceutica

                            Switzerland arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Derazantinib,Atezolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Basilea Reports Interim Results from Phase 1/2 Study Fides-02 Exploring Derazantinib in Patients with Advanced...

                            Details : Successful completion of phase 1b part of FIDES-02 exploring the safety and tolerability of combining derazantinib with PD-L1 checkpoint inhibitor atezolizumab.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 13, 2020

                            Lead Product(s) : Derazantinib,Atezolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Basilea Pharmaceutica

                            Switzerland arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Basilea Pharmaceutica

                            Switzerland arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Derazantinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Basilea Reports Pooled Efficacy Data for Derazantinib in iCCA Patients with FGFR2 Gene Mutations and Amplifica...

                            Details : FGFR inhibitors, including derazantinib, have showed clinical antitumor activity in patients with FGFR2 gene fusion-positive iCCA. To date there is limited clinical evidence for the benefit of FGFR inhibitors in iCCA patients with FGFR2 gene mutations an...

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 12, 2020

                            Lead Product(s) : Derazantinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Basilea Pharmaceutica

                            Switzerland arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Basilea Pharmaceutica

                            Switzerland arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Derazantinib,Erdafitinib

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Basilea Announces Data Presentations at ESMO Virtual Congress 2020

                            Details : The preclinical derazantinib data may provide an explanation for differences in reported adverse event profiles between various FGFR kinase inhibitors. Furthermore, derazantinib shows promising efficacy in patient-derived tumor models with gene aberratio...

                            Brand Name : ARQ 087

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 28, 2020

                            Lead Product(s) : Derazantinib,Erdafitinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth